**Author details**

Sana Komal1 , Sana Nadeem1 , Zahra Faheem1 , Arouma Raza1 , Komal Sarwer1 , Hijab Umer1 , Samina Roohi<sup>2</sup> and Syed Ali Raza Naqvi1 \*

1 Department of Chemistry, Government College University, Faisalabad-38000, Pakistan

2 Isotope Production Division, Pakistan Institute of Nuclear Science and Technology (PINSTECH), Nilore-Islamabad, Pakistan

\*Address all correspondence to: draliraza@gcuf.edu.pk

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**113**

899-906.

**14**(47): p. 19.

*Localization Mechanisms of Radiopharmaceuticals DOI: http://dx.doi.org/10.5772/intechopen.94099*

radiation and isotopes, 1969. **20**(6): p.

[10] Ancri, D., et al., *Diagnosis of cerebral lesions by thallium 201.* Radiology, 1978.

[11] Ancri, D. and J. Basset, *Diagnosis of cerebral metastases by thallium 201.* The British journal of radiology, 1980.

*scinTIGraphy with 99mTc pertechnetate, 99mTc polyphosphate, and 67Ga citrate.* Radiology, 1974. **112**(1): p. 123-130.

*(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.* Cancer research, 1990. **50**(7): p.

437-445.

**128**(2): p. 417-422.

**53**(629): p. 443-453.

2198-2202.

**37**(9): p. 1551-1556.

Research, 2017. **7**.

**26**(3): p. 283-293.

[12] Jones, A.E., et al., *Brain* 

[13] Delmon-Moingeon, L.I., et al., *Uptake of the cation hexakis* 

[14] Arbab, A.S., et al., *Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines.* Journal of Nuclear Medicine, 1996.

[15] Rowe, S.P., et al., *Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multidrug resistance pump expression.* EJNMMI

[16] Del Vecchio, S. and M. Salvatore, *99m Tc-MIBI in the evaluation of breast cancer biology.* European journal of nuclear medicine and molecular imaging, 2004. **31**(1): p. S88-S96.

[17] Moretti, J.-L., et al., *To use MIBI or not to use MIBI? That is the question when assessing tumour cells.* European journal of nuclear medicine and molecular imaging, 2005. **32**: p. 836-42.

[18] Hendrikse, N., et al., *Visualization of multidrug resistance in vivo.* European journal of nuclear medicine, 1999.

[1] Holland, J.P., *The* 

**References**

220-41.

[3] Vallabhajosula, S. and A. Owunwanne, *Basis of* 

*Radiopharmaceutical chemistry of seldom-used radionuclides in nuclear medicine*, in *Radiopharmaceutical Chemistry*. 2019, Springer. p. 425-446.

[2] Vallabhajosula, S., R.P. Killeen, and J.R. Osborne, *Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors.* Semin Nucl Med, 2010. **40**(4): p.

*Radiopharmaceutical Localization*, in *The Pathophysiologic Basis of Nuclear Medicine*. 2015, Springer. p. 45-68.

[4] Chamberlain, M.C. and J. Corey-Bloom, *Leptomeningeal metastases: 111Indium-DTPA CSF flow studies.* Neurology, 1991. **41**(11): p. 1765-1765.

[5] Bunker, S.R., et al., *Detection of Gastrointestinal Bleeding Sites: Use of In Vitro Technetium Tc 99m—Labeled RBCs.*

JAMA, 1982. **247**(6): p. 789-792.

[6] Shaffer, E., P. McOrmond, and H. Duggan, *Quantitative cholescintigraphy: assessment of gallbladder filling and emptying and duodenogastric reflux.* Gastroenterology, 1980. **79**(5): p.

[7] Hauser, W., et al., *Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning.* Radiology,

[8] Brazil, R., *A barrier to progress: getting drugs to the brain.* Evaluation, 2020.

[9] Welch, M., M. Adatepe, and E. Potchen, *An analysis of technetium (99mTcO4−) kinetics: The effect of perchlorate and iodide pretreatment.* The International journal of applied

1970. **94**(3): p. 679-684.

*Localization Mechanisms of Radiopharmaceuticals DOI: http://dx.doi.org/10.5772/intechopen.94099*
